HMS by AbbVie is clinical pharmacology hms (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Approved for allergic conjunctivitis, vernal conjunctivitis, episcleritis and 1 more indications. First approved in 1969.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
HMS (medrysone) is a synthetic corticosteroid ophthalmic suspension approved in 1969 for topical anti-inflammatory treatment of allergic and vernal conjunctivitis, episcleritis, and epinephrine sensitivity. It works by inhibiting edema, fibrin deposition, capillary dilation, and phagocytic migration characteristic of acute ocular inflammation. Medrysone has lower anti-inflammatory potency than dexamethasone, positioning it as a moderate-strength option in the topical ocular corticosteroid class.
Product is in late-stage maturity with moderate competitive pressure (30/100), indicating reduced growth investment and potential team consolidation.
CLINICAL PHARMACOLOGY HMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation,…
Worked on HMS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Out-of-office Monitoring for Rhythms Of Normal Versus Atrial Fibrillation
A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes
Modulation of Brain Rhythms in Stroke
Utilising Hull Lung Health Study Data to Investigate the Performance of TidalSense Diagnostic Algorithms to Identify COPD and Pre-COPD Among Participants in the FRONTIER Programme.
SAS 1: Develop Ocular Disease (OSD) Diagnostic, Algorithms, and Management Protocols for Cataract Surgery
Zero linked jobs reflect the mature, low-growth stage of this 55-year-old product with no active hiring pipeline. Career opportunities are limited to maintenance roles in a consolidating ophthalmology portfolio rather than strategic expansion or launch responsibilities.